These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38264525)

  • 21. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
    Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
    Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
    Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
    Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
    Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
    World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
    J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome.
    Gbadegesin R; Hinkes B; Vlangos C; Mucha B; Liu J; Hopcian J; Hildebrandt F
    Pediatr Nephrol; 2007 Apr; 22(4):509-13. PubMed ID: 17216259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of T lymphocyte subsets, immunoglobulin and complement expression in peripheral blood of children with steroid-dependent nephrotic syndrome/frequently relapsing nephrotic syndrome.
    Chen S; Wang J; Liang S
    Am J Transl Res; 2021; 13(3):1890-1895. PubMed ID: 33841716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
    Maxted AP; Dalrymple RA; Chisholm D; McColl J; Tse Y; Christian MT; Reynolds BC
    Pediatr Nephrol; 2019 May; 34(5):855-863. PubMed ID: 30564878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome.
    Fujinaga S; Nishino T; Endo S; Umeda C; Watanabe Y; Nakagawa M
    Pediatr Nephrol; 2020 Oct; 35(10):2003-2008. PubMed ID: 32556955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between HLA alleles and sub-phenotype of childhood steroid-sensitive nephrotic syndrome.
    Lee H; Wang L; Ni FF; Yang XY; Feng SP; Gao XJ; Chi H; Luo YT; Chen XL; Yang BH; Wan JL; Jiao J; Wu DQ; Zhang GF; Wang M; Yang HP; Chan H; Li Q
    World J Pediatr; 2022 Feb; 18(2):109-119. PubMed ID: 34973118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.
    Zurowska A; Drozynska-Duklas M; Topaloglu R; Bouts A; Boyer O; Shenoy M; Vivarelli M;
    Pediatr Nephrol; 2023 Sep; 38(9):3035-3042. PubMed ID: 37014530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera
    Han X; Zhang M; Wang H; Zhang Q; Li W; Hao M; Gao Y; Jin J; Ren H; Tang Y; Hong X; Ke X; Su H; Gui L; Luo J; Xie L; Gai W; Shi Y
    Chin J Cancer Res; 2022 Dec; 34(6):601-611. PubMed ID: 36714342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases.
    Riva N; Brstilo L; Sancho-Araiz A; Molina M; Savransky A; Roffé G; Sanz M; Tenembaum S; Katsicas MM; Trocóniz IF; Schaiquevich P
    Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic rituximab administration in children with complicated nephrotic syndrome.
    Okutsu M; Kamei K; Sato M; Kanamori T; Nishi K; Ishiwa S; Ogura M; Sako M; Ito S; Ishikura K
    Pediatr Nephrol; 2021 Mar; 36(3):611-619. PubMed ID: 32995922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Lin LH; Ghasemi M; Burke SM; Mavis CK; Nichols JR; Torka P; Mager DE; Hernandez-Ilizaliturri FJ; Goey AKL
    Target Oncol; 2023 Sep; 18(5):685-695. PubMed ID: 37632592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term outcomes of childhood steroid-sensitive nephrotic syndrome].
    Ying DJ; Jiang MJ; Chen LZ; Rong LP; Wu JY; Mo Y; Jiang XY
    Zhonghua Er Ke Za Zhi; 2023 Jul; 61(7):620-625. PubMed ID: 37385805
    [No Abstract]   [Full Text] [Related]  

  • 38. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.
    Chua HC; Tse A; Smith NM; Mergenhagen KA; Cha R; Tsuji BT
    Int J Antimicrob Agents; 2021 Mar; 57(3):106269. PubMed ID: 33358761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.